3Q EARNINGS: Merck's Januvia sales fall, quarterly results miss targets
This article was originally published in Scrip
Executive Summary
Merck & Co said sales of its largest drug, the diabetes treatment Januvia, fell in a quarter marked by lower than expected profit and revenue plus write offs for job cuts.